+1-786-628-7980
Sign Up/Sign In 
Nordic Nanovector ASA, clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that its CEO, Erik Skullerud will present a corporate overview via live webcast at DNB’s 12th Nordic Healthcare Conference on 16 December 2021. The presentation will take place from 10:15-10:35 CET (CET).
The presentation will be available at the same time at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Presentations.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media enquiries
Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 207 638 9571
Email: nordicnanovector@medistrava.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
